Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23002557 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL18330214 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL16914257 | 0.79 | USP2 (0.45) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL20337394 | 0.78 | GPR119 (0.39) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL31184216 | 0.78 | GPR119 (0.39) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL20337395 | 0.78 | GPR119 (0.39) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL20337397 | 0.78 | GPR119 (0.39) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL31336522 | 0.77 | USP2 (0.38) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL29366691 | 0.77 | USP2 (0.38) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL19641205 | 0.75 | USP2 (0.37) | USP2SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | PTPN5, PTPN7, PTPN1 | USP2 2291/4885SMN1; SMN2 3575/4885KDM4E 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.